As of 2026-09-28, the EV/EBITDA ratio of SAGE Therapeutics Inc (SAGE) is -1.62. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SAGE's latest enterprise value is 477.44 mil USD. SAGE's TTM EBITDA according to its financial statements is -294.68 mil USD. Dividing these 2 quantities gives us the above SAGE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.5x - 16.8x | 16.5x |
| Forward P/E multiples | 19.9x - 23.8x | 22.2x |
| Fair Price | (92.14) - (77.78) | (89.75) |
| Upside | -1161.6% - -996.1% | -1134.0% |
| Date | EV/EBITDA |